4D Molecular Therapeutics (FDMT) Change in Accured Expenses (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Change in Accured Expenses of -$4.1 million for Q1 2026, down 78.33% year-over-year from -$19.0 million in Q1 2025, and down 273.82% quarter-over-quarter from $2.4 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Change in Accured Expenses (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Change in Accured Expenses for 7 consecutive years, with -$4.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 78.33% year-over-year to -$4.1 million; the TTM figure through Mar 2026 stood at $6.3 million (down 3.94% YoY), while the FY2025 annual figure was $8.2 million, up 24.95% from the prior year.
- Change in Accured Expenses slipped to -$4.1 million in Q1 2026 per FDMT's latest filing, from $2.4 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $8.1 million in Q3 2024 and bottomed at -$4.1 million in Q1 2026.
- Historically, Change in Accured Expenses has averaged $965235.3 across 5 years, with a median of $1.2 million in 2023.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 240.75% — and 2024, when it slumped 218.48%.
- 4D Molecular Therapeutics' Change in Accured Expenses stood at $1.8 million in 2022, then climbed by 9.54% to $2.0 million in 2023, then plunged by 218.48% to -$2.4 million in 2024, then soared by 200.25% to $2.4 million in 2025, then slumped by 273.82% to -$4.1 million in 2026.
- Business Quant data shows FDMT's Change in Accured Expenses at -$4.1 million in Q1 2026, $2.4 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 6.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.54 Mn |
| Jun 30, 2026 | 6.54 Mn |
| Mar 31, 2026 | -4.12 Mn |
| Mar 31, 2026 | -4.12 Mn |
| Dec 31, 2025 | 2.37 Mn |
| Dec 31, 2025 | 2.37 Mn |
| Sep 30, 2025 | 4.98 Mn |
| Sep 30, 2025 | 4.98 Mn |
| Jun 30, 2025 | 3.11 Mn |
| Jun 30, 2025 | 3.11 Mn |
| Mar 31, 2025 | -2.31 Mn |
| Mar 31, 2025 | -2.31 Mn |
| Dec 31, 2024 | -2.37 Mn |
| Dec 31, 2024 | -2.37 Mn |
| Sep 30, 2024 | 8.11 Mn |
| Sep 30, 2024 | 8.11 Mn |
| Jun 30, 2024 | 3.17 Mn |
| Jun 30, 2024 | 3.17 Mn |
| Mar 31, 2024 | -2.39 Mn |
| Mar 31, 2024 | -2.39 Mn |